#VWA Experience Shared
Advisory Board Members
Professor, Flinders University and Founder, Chairman, and Chief Scientific Officer, Vaxine, Australia
Jerome H. Kim, M.D
Director General, International Vaccine Institute, South Korea
Yiwu He, PHD, MBA,
Senior advisor to the President and Chief Innovation Officer, The university of Hongkong
Director, Manufacturing & Supply Chain Networks, CEPI
Director, CMC R&D, Hilleman Laboratory
Chief Technology Officer, Baiya Phytopharm
Ada Wong, Project Lead, Sanofi
Sustainable Manufacturing Lead, CEPI
Commercial Manufacturing Lead, CEPI
Dr. Xuefeng Yu
CEO, CanSino Biologics Inc
External R&D, Scientific Affairs, Vice President, CanSino Biologics Inc.
Lara Elize Lamigo-Itao
Pharmacist III - Biologicals Manufacturing Division- Storage and Distribution Department, Department of Health – Philippines
Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation
Technical Advisor- Global Vaccine Markets, Clinton Health Access Initiative
Infectious Diseases Research Network Chair, College of Medicine, Qatar University
Senior Scientist, National Institute of Virology Pune
Country Director, Emory University
DBT/Wellcome Trust India Alliance Early Career Fellow, International Centre for Genetic Engineering and Biotechnology
Attendees Representing Vaccine Manufacturers, Institutes, Regulators
Companies From India, China, Africa, Brazil, Russia And More!
Speakers Sharing Their Expertise
In-Person Networking Hours
Due to increasing healthcare expenditure, advancing vaccine technology, and rising demand for preventive vaccines, especially new COVID-19 vaccines, the Asia-Pacific preventive vaccines market will rise by 12.89% annually with a total addressable market cap of $97.2 billion between 2020 and 2026.
Coronavirus infection has recently infected millions of people all over the world. In certain areas, community transmission has resulted in an increase in global casualties. At present, Big pharma and biopharma are concentrating their efforts on COVID-19 vaccine research and development. The COVID-19 pandemic situation has generated unprecedented demand, and companies are heavily investing in R&D activities, with government support as well as technological advancement to shorten the clinical trial duration and increase production efficiency. The market's growth prospects will be bolstered by the expansion of vaccine manufacturing facilities to meet the rising demand.
Vaccine World Asia Congress 2022 will be the only vaccine-focused platform in Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the Big Pharmas, International Biopharma, Asian Biopharma, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers, and Technocrats.
With this edition of Vaccine World Asia, we have co-located with Asia-Pacific Vaccine Excellence Awards. If Asia’s vaccine business matters to you, then Vaccine World Asia Congress 2022 is the place to be!
Vaccine World Asia Congress will be the only vaccine focused platform in Singapore for Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the BIG Pharmas, International Biopharma’s, Asian Biopharmas, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers and Technocrats. If Asia’s vaccines business matters to you, then Vaccine World Asia 2022 is the place to be!
COVID-19 Vaccine Action Plan in Asian Countries
Effective Strategies to Produce and Manufacture COVID-19 Vaccine at Scale and Pace
Ramping Up COVID-19 Vaccine Fill & Finish Capacity
Vaccines for Emerging Viral Diseases
Clinical Trial Results from Next- Gen and New Pipelines in the Industry
New Approaches to Evaluating Vaccine Quality Control & Safety
Production and Tech Transfers to Speed Up Local Vaccine Production
Whole-Microbe & Genetic Approach of Vaccine Development
The Way Forward for Vaccine Development and the Challenges Ahead
We deliver and implement rapid and cost-effective Biomanufacturing solutions from early phase development through scale-up to commercial manufacturing. Benefit from the most comprehensive bioprocess technology portfolio coupled with our expertise in Single-use bioprocess engineering. Our global bioprocess teams are available to discuss your process development and manufacturing requirements.
The world’s first “Vial-to-Harvest” Vaccine manufacturing platform with Linear scalability & ultimate process efficiency.
With decades of developmental efforts & experience in Bioprocess Engineering, we have solved the most critical problems of adherent cell culture processing i.e. 1) Lack of process scalability 2) Efficiency in terms of time to market 3) Affordability in terms of cost reduction in manufacturing process.
At OmniBRx, we have invented a novel bioreactor technology for large-scale biologics / vaccines production and stem-cell therapy use. The technology provides 10X Scalability, 6X efficiency and up to 90% cost reduction during upstream manufacturing processing.
Our patented “CellBRx®️” single-use bioreactors technology is the first-of-its-kind bioreactor devices offering a fully automated and robust platform for vaccine manufacturing with linear scalability of up to 200L bioreactor volume accommodating 1500 m2 of surface area per single-use bioreactor. The proprietary DBR technology employs parallel discs stacked on multiple shafts and the intermingling rotational arrangement of the discs ensures efficient mixing and homogeneity throughout the cell carrier matrix.
With the integrated seed-train development protocol, the technology becomes the first ever close-circuit fully-automated Vial-to-Harvest production platform. The CellBRx bioreactors can grow cells in high densities and recover them efficiently with complete end-to-end process automation.
Datwyler is a leading industrial supplier and a key player in the global health care world.
Our state-of-the-art solutions for drug packaging and medical devices, build on over 100 years of experience. Within our healthcare offering, we provide a unique range of products and services including the most advanced elastomer formulations, coatings, aluminum
seals, and processing technologies. Partnering up with the world’s top pharmaceutical and medical companies, we are a vital link and stand by our mission to ensure all patient’s safety and improve patients’ lives.
For more infromation, please visit: https://datwyler.com/
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.
ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from humans to other common species. All of our products are produced with high quality and batch-to-batch consistency to satisfy the rigorous standards of pharmaceutical research and development.
As ACROBiosystems' only distributor in India, Allianz BioInnovation is an ISO 9001: 2015 Certified Biotech company offering innovative Life Science Research tools from renowned companies across the world who are world leaders in their respective fields. The company has gained recognition, success and growth to its present position of a leading distributor as a result of our focus on scientist’s research needs and by following three principle viz; value, service and support.
URL link/website: https://www.acrobiosystems.com/
With more than 130 years of experience, Dr. Paul Lohmann® is a German expert in salt manufacturing and provides DPL-BioPharm Salts for the biopharmaceutical industry. These salts act as nutrients for cell cultures, as buffering and post-harvest processing agents within upstream processing. For downstream processing various acetates, citrates, phosphates and sulfates enable efficient bioprocesses for separation, precipitation and purification.
ABOUT CHIME BIOLOGICS
Chime Biologics, a China-based, world-class Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide one stop comprehensive solution supporting our customers from early-stage biopharmaceutical development through late-stage clinical and commercial manufacturing, catering to the evolving needs of the dynamic biopharmaceutical industry. We pledge to make world-class biopharmaceuticals affordable and accessible to all patients globally through manufacturing innovation, and empowering therapeutic advancement for improvement of human health.
With our State-of-the-art facility and in-house world class expert team, we are committed for excellence upholding highest degree of integrity. We are ISO 14001:2015 and ISO 45001:2018 certified. Our World’s first GE KuBio facility is located at Wuhan’s BioLake biotech industry development zone of China, with clear path to expand the total capacity up to 140,000+ in the near future.
Phone:+86 27 8787 9208
Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
Cold Chain Platform (CCP) is 100% focused on cold chain and logistics in the biopharmaceutical, life science, and healthcare industries. CCP services help global companies reach the right partners and get a firm foothold in the Asia Pacific. CCP works with global organizations to help them gain access to the APAC cold chain, logistics, and pharmaceutical market through a highly targeted audience.
DBT/Wellcome Trust India Alliance (India Alliance) is an independent, dynamic public charity that funds research in health and biomedical sciences in India. India Alliance invests in transformative ideas and supportive research ecosystems to advance discovery and innovation to improve health and well-being. India Alliance encourages diversity, inclusivity, and transparency in science and works to facilitate engagement of science with society.
Present your expertise to the key vaccines stakeholders from developing economies through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.